Amgen Inc. (NASDAQ:AMGN) Shares Sold by DF Dent & Co. Inc.

DF Dent & Co. Inc. lowered its position in Amgen Inc. (NASDAQ:AMGN) by 25.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,933 shares of the medical research company’s stock after selling 667 shares during the period. DF Dent & Co. Inc.’s holdings in Amgen were worth $623,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new position in Amgen in the third quarter valued at about $25,000. Strategic Financial Concepts LLC purchased a new position in Amgen in the second quarter valued at about $26,000. Hershey Financial Advisers LLC purchased a new position in Amgen in the second quarter valued at about $30,000. nVerses Capital LLC purchased a new position in Amgen in the second quarter valued at about $31,000. Finally, Bbjs Financial Advisors LLC purchased a new position in Amgen in the second quarter valued at about $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 0.6 %

Shares of NASDAQ AMGN opened at $272.58 on Friday. Amgen Inc. has a 52-week low of $257.80 and a 52-week high of $346.85. The firm has a fifty day moving average of $306.58 and a 200-day moving average of $315.82. The stock has a market capitalization of $146.52 billion, a PE ratio of 34.90, a P/E/G ratio of 3.08 and a beta of 0.55. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same period in the previous year, the company earned $4.96 EPS. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. On average, analysts anticipate that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 3.30%. Amgen’s dividend payout ratio is presently 115.24%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AMGN. Robert W. Baird reaffirmed an “underperform” rating and issued a $215.00 target price on shares of Amgen in a report on Wednesday, September 25th. Barclays increased their target price on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research note on Tuesday, October 22nd. Sanford C. Bernstein initiated coverage on shares of Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 price objective for the company. Finally, Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research note on Monday, September 16th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $323.05.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.